Texas-based Petrus Lta has invested 0.09% in Sucampo Pharmaceuticals, Inc. In addition, given that certain Sucampo stockholders holding approximately 32% of the outstanding Sucampo shares have entered into a tender and support agreement for this transaction, the investigation concerns whether the Sucampo Pharmaceuticals, Inc. Trexquant Investment L P has invested 0.03% of its portfolio in Sucampo Pharmaceuticals, Inc.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Sucampo Pharmaceuticals by 1.0% in the 2nd quarter.
Sucampo Pharmaceuticals, Inc.is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Raymond James & Associates now owns 16,603 shares of the biopharmaceutical company's stock valued at $182,000 after buying an additional 1,781 shares in the last quarter. In the most recent quarterly financial report, for the quarter ending Sep. Prudential Financial Inc. now owns 410,323 shares of the biopharmaceutical company's stock worth $4,842,000 after purchasing an additional 368,090 shares during the last quarter. Finally, Aperio Group LLC bought a new stake in Sucampo Pharmaceuticals in the third quarter valued at about $137,000. State Board of Administration of Florida Retirement System now owns 64,269 shares of the biopharmaceutical company's stock worth $758,000 after purchasing an additional 15,944 shares during the last quarter. More interesting news about Sucampo Pharmaceuticals, Inc.
BlackRock Inc. cut its position in shares of Sucampo Pharmaceuticals, Inc. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37. The firm has a market capitalization of $867.45, a P/E ratio of -5.55, a PEG ratio of 5.07 and a beta of 1.45. The stock, as of last close, traded 97.85% away to its 52 week low and was at a distance of 1.10% from its 52 week high.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its earnings results on Wednesday, November 9th. According to the Analysts, the Low Earnings estimate for the current quarter is $0.15, while the High earnings estimate is $0.26.Comparatively, EPS for the same quarter previous year was $0.03. The company had revenue of $61.27 million for the quarter, compared to analysts' expectations of $58.05 million. The company's net profit margin has achieved the current level of -60.2 percent and possesses 72.8 percent gross margin.
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)'s earnings per share has been growing at a 24.8 percent rate over the past 5 year when average revenue increase was noted as 33.3 percent.
Barcelona unveil Yerry Mina at Nou Camp with Colombian going barefoot
The 23-year-old Mina is being brought in as a long-term option and will not walk straight into the first team. With the work that we will all do, I will fight to be at the World Cup.
A number of other brokerages have also recently weighed in on SCMP. Mizuho downgraded Sucampo Pharmaceuticals from a buy rating to a neutral rating and dropped their price target for the stock from $14.00 to $12.00 in a research note on Tuesday, October 3rd. ValuEngine raised Sucampo Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Sunday, December 31st.
When it comes to the Analysis of a Stock, Price Target plays a vital role.
Among 10 analysts covering Coherus Biosciences (NASDAQ:CHRS), 9 have Buy rating, 0 Sell and 1 Hold. The stock has an average rating of Buy and a consensus target price of $21.58.
In other news, insider Peter A. Kiener sold 50,000 shares of Sucampo Pharmaceuticals stock in a transaction dated Thursday, December 7th. This metric reflects the average amount a stock's price has differed from the mean over a period of time. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
TRADEMARK VIOLATION NOTICE: This piece was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & global copyright & trademark law.
2017, Sucampo Pharmaceuticals, Inc. Sucampo has two marketed products - AMITIZA, its lead product, and RESCULA - and a late-stage pipeline of product candidates in clinical development for orphan disease areas.
- Ellen DeGeneres, Oprah Winfrey talk about deadly mudslides
- Joe Root returns to fitness for England's ODI opener against Australia
- Seahawks Likely to Hire Coach Brian Schottenheimer as New Offensive Coordinator
- Iran rejects Trump's demand for changing nuclear deal
- Message telling Hawaiian's to shelter from missile was 'error'
- Pope leads baptism ceremony for babies in Sistine Chapel
- No immigrati da Haiti e Africa, sono cesso di Paesi
- Macron wants French baguette to get UNESCO heritage status
- Rex Burkhead and Mike Gillislee likely out against Titans
- Acre Thomas Fire in Southern California Now 100% Contained